Identification of anti-cancer drug resistance related microRNAs and its role in colorectal tumors
Project/Area Number |
16K09329
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Research Field |
Gastroenterology
|
Research Institution | Fujita Health University |
Principal Investigator |
|
Research Collaborator |
Akao Yukihiro
|
Project Period (FY) |
2016-04-01 – 2019-03-31
|
Project Status |
Completed (Fiscal Year 2018)
|
Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2018: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2017: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2016: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
Keywords | 大腸癌 / microRNA / 抗癌剤 / 薬剤耐性 / 5-fluorouracil / drug resistance / colorectal cancer / Warburg effect |
Outline of Final Research Achievements |
We established four types of 5-FU resistant colon cancer cell line in vitro and in vivo. We then analyzed miRNA expression profile by miRNA array in these 4 cell lines, and identified the drug resistance-related miRNAs. We identified possible miRNAs to be involved in 5-FU resistance by miRNA arrays. We then examined the relationship between miR-31, which was most promising among them, and drug resistance. When we exposed high dose of 5-FU to parent or 5-FU resistant cells, the expression levels of miR-31 were raised higher than those of controls. Notably, the expression levels of miR-31 were positively correlated with the grade of clinical stages of colorectal tumors. The protein expression levels of factor inhibiting hypoxia-inducible factor 1 (FHI-1) were downregulated by transfection of mimic miR-31 into DLD-1 cells. This study provides evidence supporting the association of miR-31 with 5-FU drug resistance and clinical stages of colorectal tumors.
|
Academic Significance and Societal Importance of the Research Achievements |
実臨床では投与開始直後は抗癌剤が良く効いていても耐性が出来て効き目が悪くなり副作用ばかりが目立つことはしばしば観察される。 本研究は薬剤耐性にmicroRNAがどのように関与するかを調べた。この研究成果は抗癌剤の効果が期待できるかどうかの予測や、効きが悪くなったときにもう一度効果が出るようにするための臨床応用が期待できる。
|
Report
(4 results)
Research Products
(7 results)